Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
BCL2
BCL6
DLBCL
HGBL
MYC
genetic alterations
prognostic subgroups
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
revised:
14
10
2023
received:
05
07
2023
accepted:
16
10
2023
medline:
29
10
2023
pubmed:
29
10
2023
entrez:
28
10
2023
Statut:
aheadofprint
Résumé
High-grade B-cell lymphoma (HGBL)/diffuse large B-cell lymphoma (DLBCL) with rearrangements (R) in MYC and BCL2 and/or BCL6 are correlated with poor prognosis. Little is known about the impact of other genetic alterations (gain (G) or amplification (A)) of these genes. The aim of the study was to investigate whether we can identify new prognostic subgroups. Fluorescence in situ hybridization (FISH) results from 169 HGBL/DLBCL were retrospectively categorized into: (1) concurrent MYC-R and BCL2-R and/or BCL6-R-samples with MYC-R and BCL2-R (+/- BCL6-R); n = 21, and HGBL/DLBCL with MYC-R and BCL6-R; n = 11; (2) concurrent R and G/A in MYC and BCL2 and/or BCL6 called "alternative HGBL/DLBCL"-samples with (n = 16) or without (n = 6) BCL2 involvement; (3) BCL2 and/or BCL6 alterations without MYC involvement (n = 35); (4) concurrent G/A in MYC and BCL2 and/or BCL6 without R (n = 25); and (5) "No alterations" (n = 55). Patients with HGBL/DLBCL-MYC/BCL2 and "alternative" HGBL/DLBCL (with BCL2 involvement) had significantly worse survival rates compared to the "no alterations" group. G/A of these genes in the absence of rearrangements did not show any prognostic significance. HGBL/DLBCL with MYC-R and BCL6-R without BCL2 involvement showed a better survival rate compared to HGBL/DLBCL-MYC/BCL2. According to immunohistochemistry, "double/triple" expression (DEL/TEL) did not show a significantly worse outcome compared to absent DEL/TEL. This study highlights the continued value of FISH assessment of MYC, BCL2, and BCL6 in the initial evaluation of HGBL/DLBCL with different survival rates between several genetic subgroups.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. revised 5th edn. International Agency for Research on Cancer; 2022 586pp.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. revised 4th edn. International Agency for Research on Cancer; 2016.
Oliveira CC, Domingues MAC. Double-hit and triple-hit lymphomas: new perspectives for their classification. EMJ Hematol. 2017;5(1):95-103.
Swerdlow SH. Diagnosis of ‘double-hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology. 2014;2014:90-99.
Chisholm KM, Bangs CD, Bacchi CE, et al. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39:294-303.
Young OC, Mederios J. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology. 2020;52(1):68-77.
Alsuwaidan A, Pirruccello E, Jaso J, et al. Bright CD38 expression by flow cytometric analysis is a biomarker ford double/triple hit lymphomas with a moderate sensitivity and high specificity. Clin Cytom. 2019;968:368-374.
Krull JE, Wenzl K, Hartert KT, et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020;10:117-126.
Li S, Seegmiller AC, Lin P, et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 2015;28:208-217.
Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229-1253.
Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;15:4622-4632.
Ting C, Chang K, Kuan J, et al. Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, Epstein-Barr virus infection, CD5 protein expression, germinal center B cell-non-germinal center B-cell subtypes, co-expression of MYC/BCL2 proteins and co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: a clinical and pathological correlation study of 120 patients. Int J Med Sci. 2019;16(4):556-566.
Johnson S, Umakanthan J, Yuan J, et al. Lymphomas with pseudo-double-hit BCL6/MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. Hum Pathol. 2018;80:192-200.
Landsburg D, Petrich A, Abramson JS, et al. Impact of oncogene rearragement patterns on outcomes in double-hit non-Hodgkin lymphoma patients. Cancer. 2016;122(4):559-564.
Ryan R, Drier Y, Whitton H, et al. Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. Cancer Discov. 2015;5(10):1058-1071.
Petrich A, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120:3884-3895.
King RL, McPhail ED, Meyer RG, et al. False-negative rates for MYC FISH probes in B-cell neoplasms. Haematologica. 2019;104(6):e248-e251.